甲状腺与心血管疾病:增强知识、预防和治疗的研究议程
2017年9月,美国国家心肺血液研究所工作组召开会议,旨在制定甲状腺功能障碍与心血管疾病进展相关的未来研究优先事项。工作组审查了甲状腺生理、功能障碍后果及治疗在三个心血管领域的作用,并提出了三大研究方向。
要点
- 甲状腺激素对心血管系统有多方面影响,但分子机制和管理策略存在知识缺口。
- 研究应聚焦甲状腺功能障碍与心血管疾病的基础生物学及新型生物标志物。
- 需定义可从预防和介入治疗中获益的甲状腺功能障碍患者亚组,并开展改善心血管结局的临床试验。
核心结论
- 工作组建议研究聚焦于甲状腺功能障碍与心血管疾病的基础生物学、患者亚组识别以及甲状腺激素或拟甲状腺药物改善心血管结局的临床试验。
研究设计与样本
- 2017年9月美国国家心肺血液研究所召集工作组,审查甲状腺生理、功能障碍后果及治疗在三个心血管领域的作用。
主要发现
- 工作组讨论了甲状腺功能正常生理、甲状腺功能障碍后果及治疗在心脏电生理与心律失常、血管与动脉粥样硬化、心肌与心力衰竭三个领域的作用。
关键数值与推荐
- 建议研究三大领域:基础生物学与新型生物标志物;定义可受益于预防和介入治疗的患者亚组;通过甲状腺激素或拟甲状腺药物改善心血管表现和结局的临床试验。
临床怎么用
- 临床应关注甲状腺功能障碍对心律失常、动脉粥样硬化和心力衰竭的影响,并参与定义可干预的患者亚组。
局限性
- 原文未报告具体研究数据、样本量或统计值,仅为研究议程报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Thyroid hormones have long been known to have a range of effects on the cardiovascular system. However, significant knowledge gaps exist concerning the precise molecular and biochemical mechanisms governing these effects and the optimal strategies for management of abnormalities in thyroid function in patients with and without preexisting cardiovascular disease. In September 2017, the National Heart, Lung, and Blood Institute convened a Working Group with the goal of developing priorities for future scientific research relating thyroid dysfunction to the progression of cardiovascular disease. The Working Group reviewed and discussed the roles of normal thyroid physiology, the consequences of thyroid dysfunction, and the effects of therapy in 3 cardiovascular areas: cardiac electrophysiology and arrhythmias, the vasculature and atherosclerosis, and the myocardium and heart failure. This report describes the current state of the field, outlines barriers and challenges to progress, and proposes research opportunities to advance the field, including strategies for leveraging novel approaches using omics and big data. The Working Group recommended research in 3 broad areas: (1) investigation into the fundamental biology relating thyroid dysfunction to the development of cardiovascular disease and into the identification of novel biomarkers of thyroid hormone action in cardiovascular tissues; (2) studies that define subgroups of patients with thyroid dysfunction amenable to specific preventive strategies and interventional therapies related to cardiovascular disease; and (3) clinical trials focused on improvement in cardiovascular performance and cardiovascular outcomes through treatment with thyroid hormone or thyromimetic drugs.
引用
- Cappola AR, Desai AS, Medici M, et al. Thyroid and Cardiovascular Disease: Research Agenda for Enhancing Knowledge, Prevention, and Treatment. Circulation. 2019. PMID: 31081673. doi:10.1161/CIRCULATIONAHA.118.036859
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。